[1] Intent-to-treat group includes all patients who were enrolled and randomly allocated to treatment and are analysed according to the group to which they were randomized. The intent-to-treat-group included n=182 (Y-90 resin microspheres) and n=178 (sorafenib).
[2] Treated group includes only those patients who completed the treatment originally allocated. The treated group included n=130 (Y-90 resin microspheres) and n=162 (sorafenib).
[3] Ferlay J et al. Globocan 2012. v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr , accessed on 18/May/2017.
[4] EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
Photo: http://mma.prnewswire.com/media/513549/N... http://mma.prnewswire.com/media/513550/S...
CONTACT: For media enquiries, please contact: National Cancer CentreSingapore, Ms Rachel Tan, Assistant Manager, Corporate Communications, Tel:+65 6236 9535 , Hp: 9754 0842 Email: rachel.tan.c.h@nccs.com.sg , MsGillian Tan Senior Executive, Corporate Communications , Tel: +65 6236 9529Hp: 8157 3671, Email: gillian.tan@nccs.com.sg
Andalucía
Aragón
Cantabria
Castilla-La Mancha
Castilla y León
Catalunya
Extremadura
Galicia
Islas Canarias
Islas Baleares
Madrid
País Vasco
La Rioja
C. Valenciana
Navarra
Asturias
Murcia
Ceuta y Melilla
